Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TI Fluid Systems PLC Regulatory Filings 2019

Apr 1, 2019

5340_rns_2019-04-01_04909fa8-ad1c-4c91-a35c-3612a175b681.html

Regulatory Filings

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5618U

TI Fluid Systems PLC

01 April 2019

1 April 2019

TI Fluid Systems plc (the "Company")

Total Voting Rights

In accordance with the Disclosure Guidance and Transparency Rules (the "Rules"), we notify the market of the following:

As at 31 March 2019, the issued capital of the Company comprised of 520,269,141 ordinary shares of 1 pence. There are no ordinary shares held in treasury and accordingly, the total number of voting rights is 520,269,141.  All of the issued ordinary shares carry voting rights of one vote per share.  This figure may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Rules.

ENDS

Enquiries:

TI Fluid Systems plc      +44 (0)1865 871824

Alpna Amar

Investor Relations          

FTI Consulting               +44 (0)20 3727 1340

Richard Mountain

Nick Hasell

About TI Fluid Systems plc

TI Fluid Systems (LSE: TIFS) is a leading global manufacturer of fluid storage, carrying and delivery systems primarily for the light duty automotive market. With nearly 100 years of automotive fluid systems experience, TI Fluid Systems has manufacturing facilities in 114 locations across 28 countries serving all major global OEMs.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

TVREAXDNAEENEFF